Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma	Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, hematologic disorder, immune system disorder, immunoproliferative disorder, monoclonal gammopathy, neoplasm, precancerous condition, smoldering plasma cell myeloma	Active, not recruiting	Phase 2	2022-09-10		NCT02415413

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Amgen	180
Celgene Corporation	20
PETHEMA Foundation	21

16 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Clínica Universidad de Navarra	Pamplona	Spain	15
Hospital Clínic de Barcelona	Barcelona	Spain	35
Hospital Clínico San Carlos	Madrid	Spain	30
Hospital Clínico Universitario de Valencia	Valencia	Spain	26
Hospital Clínico Universitario Lozano Blesa	Zaragoza	Spain	11
Hospital de Son Llàtzer	Plama de Mallorca	Spain	1
Hospital Universitari Germans Trias i Pujol	Barcelona	Spain	6
Hospital Universitario 12 De Octubre	Madrid	Spain	98
Hospital Universitario Central De Asturias	Oviedo	Spain	25
Hospital Universitario de Canarias	Santa Cruz de Tenerife	Spain	11
Hospital Universitario de Salamanca	Salamanca	Spain	29
Hospital Universitario Doctor Peset	Valencia	Spain	3
Hospital Universitario Morales Meseguer	Murcia	Spain	4
Hospital Universitario Ramón y Cajal	Madrid	Spain	42
Hospital Universitario Reina Sofía	Seville	Spain	2
Hospital Universitario Virgen del Rocío	Seville	Spain	37